| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 40 | 2021 | 638 | 7.070 |
Why?
|
| Glioblastoma | 29 | 2020 | 156 | 6.050 |
Why?
|
| Receptor, EphA2 | 9 | 2021 | 13 | 2.930 |
Why?
|
| Ephrin-A1 | 8 | 2017 | 11 | 2.690 |
Why?
|
| Glioma | 13 | 2021 | 136 | 2.610 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 8 | 2017 | 11 | 1.920 |
Why?
|
| Drug Delivery Systems | 8 | 2021 | 104 | 1.810 |
Why?
|
| Antineoplastic Agents | 10 | 2020 | 608 | 1.740 |
Why?
|
| Neoplasms | 9 | 2018 | 726 | 1.420 |
Why?
|
| Interleukin-13 | 9 | 2012 | 28 | 1.250 |
Why?
|
| Cell Line, Tumor | 23 | 2020 | 726 | 1.160 |
Why?
|
| Cytotoxins | 5 | 2021 | 13 | 1.140 |
Why?
|
| Immunotoxins | 5 | 2016 | 17 | 1.010 |
Why?
|
| Signal Transduction | 4 | 2014 | 682 | 0.970 |
Why?
|
| Proto-Oncogene Proteins c-fos | 3 | 2011 | 9 | 0.940 |
Why?
|
| Astrocytoma | 4 | 2018 | 29 | 0.870 |
Why?
|
| Peptides | 5 | 2017 | 120 | 0.850 |
Why?
|
| Humans | 63 | 2020 | 32005 | 0.840 |
Why?
|
| Receptors, Eph Family | 2 | 2014 | 2 | 0.820 |
Why?
|
| Bacterial Toxins | 5 | 2013 | 23 | 0.770 |
Why?
|
| Receptors, Interleukin | 5 | 2004 | 16 | 0.770 |
Why?
|
| Animals | 29 | 2021 | 7541 | 0.750 |
Why?
|
| Immunotherapy | 3 | 2020 | 81 | 0.730 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2019 | 261 | 0.650 |
Why?
|
| Blood-Brain Barrier | 3 | 2020 | 48 | 0.650 |
Why?
|
| Convection | 3 | 2021 | 8 | 0.630 |
Why?
|
| Binding Sites | 7 | 2013 | 130 | 0.620 |
Why?
|
| Protein Binding | 7 | 2016 | 201 | 0.590 |
Why?
|
| Cancer Vaccines | 2 | 2008 | 24 | 0.570 |
Why?
|
| Ephrin-A5 | 1 | 2016 | 2 | 0.560 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 18 | 0.560 |
Why?
|
| Cell Proliferation | 9 | 2020 | 604 | 0.540 |
Why?
|
| Mice | 16 | 2020 | 2484 | 0.540 |
Why?
|
| Ephrins | 1 | 2014 | 1 | 0.500 |
Why?
|
| Blotting, Western | 7 | 2013 | 289 | 0.490 |
Why?
|
| Ligands | 6 | 2013 | 81 | 0.490 |
Why?
|
| Brain | 4 | 2018 | 951 | 0.490 |
Why?
|
| Mice, Nude | 10 | 2020 | 291 | 0.470 |
Why?
|
| Polymers | 1 | 2013 | 64 | 0.450 |
Why?
|
| Tumor Cells, Cultured | 5 | 2016 | 170 | 0.450 |
Why?
|
| Antibodies, Monoclonal | 2 | 2013 | 246 | 0.420 |
Why?
|
| Matrix Metalloproteinases | 1 | 2012 | 11 | 0.420 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 80 | 0.400 |
Why?
|
| Peptide Library | 1 | 2011 | 6 | 0.400 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2011 | 7 | 0.380 |
Why?
|
| Genetic Vectors | 2 | 2010 | 120 | 0.380 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2020 | 115 | 0.380 |
Why?
|
| Apoptosis | 4 | 2016 | 360 | 0.380 |
Why?
|
| Molecular Sequence Data | 5 | 2013 | 359 | 0.370 |
Why?
|
| Cell Movement | 5 | 2020 | 169 | 0.370 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 6 | 2012 | 10 | 0.340 |
Why?
|
| Anticonvulsants | 1 | 2009 | 65 | 0.330 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2020 | 46 | 0.330 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 495 | 0.330 |
Why?
|
| Dogs | 3 | 2021 | 120 | 0.330 |
Why?
|
| Diphtheria Toxin | 1 | 2009 | 26 | 0.330 |
Why?
|
| Vaccines, DNA | 1 | 2008 | 4 | 0.320 |
Why?
|
| Immunotherapy, Active | 1 | 2008 | 6 | 0.320 |
Why?
|
| Transcription Factors | 3 | 2019 | 181 | 0.320 |
Why?
|
| Cell Hypoxia | 1 | 2009 | 41 | 0.320 |
Why?
|
| Photosensitizing Agents | 2 | 2018 | 24 | 0.320 |
Why?
|
| Mutation | 6 | 2013 | 489 | 0.310 |
Why?
|
| Genomics | 3 | 2018 | 85 | 0.310 |
Why?
|
| Alanine | 2 | 2012 | 27 | 0.310 |
Why?
|
| Amino Acid Sequence | 4 | 2013 | 285 | 0.310 |
Why?
|
| Neoplastic Stem Cells | 2 | 2019 | 99 | 0.300 |
Why?
|
| Oxygen | 1 | 2009 | 142 | 0.300 |
Why?
|
| Recombinant Proteins | 5 | 2012 | 247 | 0.300 |
Why?
|
| Transfection | 5 | 2015 | 191 | 0.280 |
Why?
|
| Exotoxins | 4 | 2013 | 13 | 0.270 |
Why?
|
| MicroRNAs | 2 | 2018 | 180 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 458 | 0.240 |
Why?
|
| Transgenes | 4 | 2011 | 48 | 0.240 |
Why?
|
| Receptors, Interleukin-13 | 5 | 2004 | 9 | 0.230 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2018 | 57 | 0.230 |
Why?
|
| Radiosurgery | 2 | 2019 | 356 | 0.230 |
Why?
|
| Immunization, Passive | 1 | 2003 | 9 | 0.230 |
Why?
|
| Sulfones | 2 | 2020 | 21 | 0.220 |
Why?
|
| Indans | 2 | 2020 | 31 | 0.220 |
Why?
|
| Surface Plasmon Resonance | 2 | 2013 | 7 | 0.210 |
Why?
|
| Protein Structure, Secondary | 3 | 2012 | 47 | 0.210 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2013 | 70 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2013 | 105 | 0.210 |
Why?
|
| Binding, Competitive | 2 | 2013 | 33 | 0.210 |
Why?
|
| Protein Structure, Tertiary | 2 | 2013 | 99 | 0.210 |
Why?
|
| Up-Regulation | 3 | 2018 | 189 | 0.200 |
Why?
|
| Photochemotherapy | 2 | 2018 | 21 | 0.200 |
Why?
|
| ADP Ribose Transferases | 2 | 2013 | 4 | 0.190 |
Why?
|
| Virulence Factors | 2 | 2013 | 11 | 0.190 |
Why?
|
| Electromagnetic Fields | 2 | 2018 | 26 | 0.190 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2018 | 40 | 0.180 |
Why?
|
| Female | 17 | 2019 | 19959 | 0.180 |
Why?
|
| Radiotherapy | 2 | 2018 | 82 | 0.180 |
Why?
|
| Ephrin-A2 | 2 | 2013 | 2 | 0.180 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 765 | 0.180 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2013 | 36 | 0.170 |
Why?
|
| Syndecan-1 | 1 | 2019 | 11 | 0.170 |
Why?
|
| Plasma Cells | 1 | 2019 | 11 | 0.170 |
Why?
|
| Single-Chain Antibodies | 2 | 2016 | 3 | 0.170 |
Why?
|
| Cells, Cultured | 2 | 2013 | 833 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 153 | 0.160 |
Why?
|
| Flow Cytometry | 2 | 2013 | 185 | 0.160 |
Why?
|
| Immunoconjugates | 1 | 2018 | 9 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 3 | 2016 | 82 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 22 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 19 | 0.160 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 31 | 0.160 |
Why?
|
| Gene Silencing | 2 | 2011 | 48 | 0.150 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 301 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 104 | 0.150 |
Why?
|
| Immunohistochemistry | 3 | 2015 | 538 | 0.150 |
Why?
|
| Microglia | 1 | 2018 | 57 | 0.150 |
Why?
|
| DNA Damage | 1 | 2018 | 98 | 0.150 |
Why?
|
| Exosomes | 1 | 2018 | 43 | 0.150 |
Why?
|
| Electroporation | 1 | 2017 | 14 | 0.150 |
Why?
|
| Male | 15 | 2019 | 19165 | 0.150 |
Why?
|
| Alpha Particles | 1 | 2017 | 7 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 226 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 111 | 0.140 |
Why?
|
| Receptors, Cell Surface | 2 | 2015 | 70 | 0.140 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2016 | 12 | 0.140 |
Why?
|
| Interferon-Stimulated Gene Factor 3, gamma Subunit | 1 | 2016 | 2 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 78 | 0.140 |
Why?
|
| Circular Dichroism | 3 | 2012 | 30 | 0.140 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2012 | 62 | 0.140 |
Why?
|
| Fluorodeoxyuridylate | 1 | 2016 | 23 | 0.130 |
Why?
|
| CHO Cells | 2 | 2008 | 24 | 0.130 |
Why?
|
| Cricetinae | 2 | 2008 | 39 | 0.130 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 53 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2015 | 3 | 0.130 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 471 | 0.130 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 114 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 101 | 0.120 |
Why?
|
| Cell Survival | 2 | 2007 | 284 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 148 | 0.120 |
Why?
|
| DNA Primers | 3 | 2002 | 91 | 0.120 |
Why?
|
| Recurrence | 2 | 2019 | 263 | 0.120 |
Why?
|
| Caspases | 1 | 2013 | 39 | 0.120 |
Why?
|
| Middle Aged | 10 | 2019 | 11817 | 0.110 |
Why?
|
| Triazines | 1 | 2013 | 3 | 0.110 |
Why?
|
| Dog Diseases | 1 | 2013 | 11 | 0.110 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2013 | 7 | 0.110 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 33 | 0.110 |
Why?
|
| Antigens, Surface | 1 | 2013 | 24 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 49 | 0.110 |
Why?
|
| Fluorouracil | 1 | 2013 | 81 | 0.110 |
Why?
|
| Glycosylation | 1 | 2013 | 15 | 0.110 |
Why?
|
| Protein Multimerization | 1 | 2013 | 22 | 0.110 |
Why?
|
| Crystallography, X-Ray | 1 | 2013 | 90 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 263 | 0.110 |
Why?
|
| Trans-Activators | 2 | 2011 | 46 | 0.110 |
Why?
|
| DNA Methylation | 3 | 2015 | 141 | 0.110 |
Why?
|
| Radioisotopes | 1 | 2012 | 5 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 3 | 2018 | 167 | 0.110 |
Why?
|
| Models, Molecular | 1 | 2013 | 193 | 0.110 |
Why?
|
| Cerebral Cortex | 1 | 2013 | 126 | 0.110 |
Why?
|
| Cytoplasm | 1 | 2012 | 29 | 0.100 |
Why?
|
| Protein Engineering | 1 | 2012 | 19 | 0.100 |
Why?
|
| Phosphoinositide Phospholipase C | 1 | 2012 | 3 | 0.100 |
Why?
|
| Drug Carriers | 1 | 2012 | 21 | 0.100 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 51 | 0.100 |
Why?
|
| Mutagenesis | 1 | 2012 | 33 | 0.100 |
Why?
|
| Time Factors | 2 | 2016 | 2149 | 0.100 |
Why?
|
| Transcriptional Activation | 2 | 2018 | 42 | 0.100 |
Why?
|
| Protein Conformation | 1 | 2012 | 84 | 0.100 |
Why?
|
| Protein Isoforms | 1 | 2012 | 57 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 102 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 633 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2015 | 3306 | 0.100 |
Why?
|
| Cell Physiological Phenomena | 1 | 2011 | 3 | 0.100 |
Why?
|
| Cytoskeleton | 1 | 2011 | 18 | 0.100 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2011 | 10 | 0.100 |
Why?
|
| Cell Membrane | 1 | 2012 | 96 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 105 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 412 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 2012 | 108 | 0.100 |
Why?
|
| Adult | 8 | 2019 | 9345 | 0.100 |
Why?
|
| Models, Biological | 2 | 2017 | 392 | 0.100 |
Why?
|
| Viruses | 1 | 2010 | 3 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 3990 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 77 | 0.090 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 2 | 2007 | 5 | 0.090 |
Why?
|
| Gene Expression | 2 | 2017 | 338 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 407 | 0.090 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 63 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 2 | 2007 | 48 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2011 | 189 | 0.090 |
Why?
|
| Disease Progression | 3 | 2018 | 594 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 190 | 0.090 |
Why?
|
| Neurons | 1 | 2013 | 410 | 0.090 |
Why?
|
| Aged | 7 | 2018 | 10301 | 0.090 |
Why?
|
| Catheters, Indwelling | 1 | 2009 | 43 | 0.080 |
Why?
|
| Furin | 1 | 2009 | 3 | 0.080 |
Why?
|
| Cell Line | 2 | 2007 | 435 | 0.080 |
Why?
|
| Cricetulus | 1 | 2008 | 12 | 0.080 |
Why?
|
| Autoradiography | 1 | 2008 | 45 | 0.080 |
Why?
|
| Young Adult | 4 | 2018 | 2636 | 0.080 |
Why?
|
| Pseudomonas | 2 | 2010 | 6 | 0.080 |
Why?
|
| Astrocytes | 2 | 2019 | 58 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2018 | 3509 | 0.080 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 34 | 0.080 |
Why?
|
| Adolescent | 4 | 2018 | 3539 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 2265 | 0.070 |
Why?
|
| Survival Rate | 2 | 2018 | 877 | 0.070 |
Why?
|
| HLA-A Antigens | 1 | 2005 | 2 | 0.070 |
Why?
|
| HLA-A2 Antigen | 1 | 2005 | 5 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 91 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2005 | 37 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 560 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 1 | 2005 | 19 | 0.060 |
Why?
|
| Base Sequence | 2 | 2002 | 252 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 56 | 0.060 |
Why?
|
| Dacarbazine | 2 | 2016 | 29 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 160 | 0.060 |
Why?
|
| Cell Division | 1 | 2005 | 99 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2005 | 108 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2015 | 81 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 317 | 0.060 |
Why?
|
| Protein Structure, Quaternary | 1 | 2004 | 18 | 0.060 |
Why?
|
| Prognosis | 2 | 2018 | 1497 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2005 | 508 | 0.060 |
Why?
|
| Genotype | 1 | 2005 | 733 | 0.050 |
Why?
|
| Chromosomes, Human, X | 1 | 2003 | 12 | 0.050 |
Why?
|
| Phenotype | 1 | 2005 | 632 | 0.050 |
Why?
|
| Receptors, Virus | 1 | 2002 | 14 | 0.050 |
Why?
|
| Viral Envelope Proteins | 1 | 2002 | 10 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2003 | 46 | 0.050 |
Why?
|
| Herpesvirus 1, Human | 1 | 2002 | 8 | 0.050 |
Why?
|
| DNA, Antisense | 1 | 2002 | 1 | 0.050 |
Why?
|
| Asthma | 1 | 2005 | 259 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2002 | 31 | 0.050 |
Why?
|
| Dimerization | 1 | 2002 | 23 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2002 | 22 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 75 | 0.050 |
Why?
|
| Escherichia coli | 1 | 2002 | 87 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 198 | 0.050 |
Why?
|
| Receptors, Transferrin | 1 | 2002 | 10 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2013 | 163 | 0.050 |
Why?
|
| RNA | 1 | 2002 | 92 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2003 | 767 | 0.050 |
Why?
|
| Proteins | 1 | 2002 | 144 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2015 | 1817 | 0.040 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2019 | 20 | 0.040 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2019 | 18 | 0.040 |
Why?
|
| Receptor, erbB-2 | 1 | 2019 | 65 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 166 | 0.040 |
Why?
|
| Nanomedicine | 1 | 2018 | 16 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 64 | 0.040 |
Why?
|
| Infrared Rays | 1 | 2018 | 18 | 0.040 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2018 | 13 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2018 | 82 | 0.040 |
Why?
|
| RNA Interference | 1 | 2018 | 76 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 73 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2018 | 142 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2018 | 122 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 1328 | 0.040 |
Why?
|
| Cysteamine | 1 | 2017 | 2 | 0.040 |
Why?
|
| Actinium | 1 | 2017 | 3 | 0.040 |
Why?
|
| Copper Radioisotopes | 1 | 2017 | 3 | 0.040 |
Why?
|
| Cell Size | 1 | 2017 | 38 | 0.040 |
Why?
|
| Isotope Labeling | 1 | 2017 | 16 | 0.040 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2017 | 17 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 264 | 0.040 |
Why?
|
| Cell Death | 1 | 2017 | 77 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2017 | 41 | 0.040 |
Why?
|
| Membrane Potentials | 1 | 2017 | 81 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2017 | 81 | 0.040 |
Why?
|
| Finite Element Analysis | 1 | 2017 | 82 | 0.040 |
Why?
|
| Hydrogels | 1 | 2017 | 121 | 0.030 |
Why?
|
| Collagen | 1 | 2017 | 225 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2015 | 11 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2015 | 14 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 71 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2015 | 134 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 220 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 483 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2007 | 898 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 34 | 0.030 |
Why?
|
| Perfusion Imaging | 1 | 2013 | 8 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 162 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 83 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2013 | 35 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 1022 | 0.030 |
Why?
|
| Rats | 1 | 2017 | 1595 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2007 | 835 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 1 | 2012 | 8 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2012 | 18 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 52 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2007 | 1062 | 0.030 |
Why?
|
| Prevalence | 1 | 2014 | 981 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2010 | 11 | 0.020 |
Why?
|
| Neurotoxins | 1 | 2010 | 16 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2010 | 66 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 918 | 0.020 |
Why?
|
| Europe | 1 | 2007 | 82 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2007 | 24 | 0.020 |
Why?
|
| Haplotypes | 1 | 2007 | 220 | 0.020 |
Why?
|
| STAT6 Transcription Factor | 1 | 2005 | 1 | 0.020 |
Why?
|
| ADAM Proteins | 1 | 2005 | 13 | 0.020 |
Why?
|
| Metalloendopeptidases | 1 | 2005 | 11 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 31 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 147 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2005 | 256 | 0.010 |
Why?
|
| Hemagglutinins, Viral | 1 | 2002 | 1 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2002 | 22 | 0.010 |
Why?
|
| Genome, Viral | 1 | 2002 | 10 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 2002 | 20 | 0.010 |
Why?
|
| Virus Replication | 1 | 2002 | 42 | 0.010 |
Why?
|